Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2021 - 2025)

Abeona Therapeutics (ABEO) has 10 years of Other Non-Current Liabilities data on record, last reported at $22.6 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 1951.45% year-over-year to $22.6 million; the TTM value through Sep 2025 reached $22.6 million, up 1951.45%, while the annual FY2024 figure was $32.0 million, 2.11% up from the prior year.
  • Other Non-Current Liabilities reached $22.6 million in Q3 2025 per ABEO's latest filing, down from $30.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $48.7 million in Q1 2024 and bottomed at $200000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $19.2 million, with a median of $22.6 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: soared 13461.0% in 2023, then tumbled 95.94% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $9.0 million in 2021, then skyrocketed by 118.24% to $19.7 million in 2022, then soared by 59.5% to $31.4 million in 2023, then increased by 2.11% to $32.0 million in 2024, then decreased by 29.51% to $22.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $22.6 million in Q3 2025, $30.2 million in Q2 2025, and $24.8 million in Q1 2025.